WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 47'6401 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 45'6161 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 82'652  82'727  82'800  82'893  83'017  83'512  80'487  79'169 
Births 704  702  699  697  696  768  842  827 
Surviving infants 702  699  697  695  694  765  836  817 
Pop. less than 5 years 3'503  3'475  3'451  3'442  3'458  3'989  4'442  4'076 
Pop. less than 15 years 10'755  10'830  10'913  11'012  11'133  13'036  12'938  14'659 
Female 15-49 years 17'824  18'126  18'416  18'686  18'936  20'078  19'686  19'508 

Number of reported case

(Click for retrospective incidence data for Germany)
Diphtheria 19 
Japanese encephalitis
Measles 443  1'771  166  1'607  780  28'745 
Mumps 837 
Pertussis 12'260  258 
Polio*
Rubella 151 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 18  21 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Germany)
Vaccine year result method % card seen                                                
BCG         
DTP1          99  99 
DTP3          96  96  96  96  78  80 
DTP4          96 
IPV1          99 
HepB_BD         
HepB3          88  87  86  87  90  45 
Hib3          94  94  94  93  94  82 
JapEnc         
MCV1          97  97  97  96  96  92  50 
MCV2          93  92  92  92  90 
PCV1         
PCV3          85  68  41  15 
Pol3          95  95  95  94  95  95  85 
Rota1         
Rota_last         
Rubella1          96  96  96  96  96 
TT2plus          80 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Germany)
DTP1 98  98  98  98  98  95  93 
DTP3 96  96  96  96  96  90  80 
HepB3 87  87  87  87  87  84 
HepB_BD
Hib3 94  94  94  94  94  94 
MCV1 97  97  97  97  97  92  75  25 
MCV2 92  92  92  92  92 
PCV3 68  68  68  68  68 
Pol3 95  95  95  95  95  94  80  80 
Rota_last

Number of districts in the country 402  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaP 2, 3, 4, 11-14 months; Yes
DTaPHibHepIPV 2, 3, 4, 11-14 months; Yes
DTaPHibIPV 2, 3, 4, 11-14 months; Yes
HPV 9-14 years x2; Yes females - cathch up for Y14-Y17 (x3 doses)
HepB_pediatric 2, 4, 11-14 months; Yes
Influenza_Adult Yes elderly, pregnant women, helath care workers, adults with chronic disease, travelers to Haj and other risk groups
Influenza_Pediatric Yes children with chronic disease
MMR 11-14, 15-23 months; Yes And adults born after 1970
MMRV 15-23 months; Yes
MenC_conj 11-23 months; Yes
Pneumo_conj 2, 3, 4, 11-14 months; Yes
Pneumo_ps >60 years; Yes
Rotavirus 6, 10, 14 weeks; Yes 3rd dose depending on vaccine presentation
TdaPIPV 9-17 years;
Tdap 5-6 years; Yes every 10 years
Varicella 11-14, 15-23 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 402  402  402  412  412  423  424 
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100%
Nº districts with measles (MCV1) coverage >=95% number              
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  Yes  Yes  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%   NA  NA  NA  NA     

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.